Eleni M Rettig1, Marietta Tan1, Shizhang Ling1, Raluca Yonescu2, Justin A Bishop2, Carole Fakhry1,3,4, Patrick K Ha1,3. 1. Department of Otolaryngology-Head and Neck Surgery. 2. Department of Pathology, Johns Hopkins University School of Medicine. 3. Milton J. Dance Jr. Head and Neck Center, Greater Baltimore Medical Center. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, U.S.A.
Abstract
OBJECTIVES: Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. STUDY DESIGN: Case series. METHODS: Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. RESULTS: One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI] = 131.9-191.6), and median disease-free survival was 112.0 months (95% CI = 88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend < 0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR] = 8.80, 95% CI = 1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios = 1.51, 95% CI = 1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR] = 1.53, 95% CI = 0.77-3.02, P = 0.22 and HR = 0.91, 95% CI = 0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). CONCLUSION: Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. LEVEL OF EVIDENCE: 4.
OBJECTIVES:Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. STUDY DESIGN: Case series. METHODS: Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. RESULTS: One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI] = 131.9-191.6), and median disease-free survival was 112.0 months (95% CI = 88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend < 0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR] = 8.80, 95% CI = 1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios = 1.51, 95% CI = 1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR] = 1.53, 95% CI = 0.77-3.02, P = 0.22 and HR = 0.91, 95% CI = 0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). CONCLUSION: Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. LEVEL OF EVIDENCE: 4.
Authors: Louis B Brill; William A Kanner; André Fehr; Ywonne Andrén; Christopher A Moskaluk; Thomas Löning; Göran Stenman; Henry F Frierson Journal: Mod Pathol Date: 2011-05-13 Impact factor: 7.842
Authors: Marta Persson; Ywonne Andrén; Christopher A Moskaluk; Henry F Frierson; Susanna L Cooke; Philip Andrew Futreal; Teresia Kling; Sven Nelander; Anders Nordkvist; Fredrik Persson; Göran Stenman Journal: Genes Chromosomes Cancer Date: 2012-04-16 Impact factor: 5.006
Authors: Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2010-08-11 Impact factor: 12.531
Authors: Yoshitsugu Mitani; Pulivarthi H Rao; P Andrew Futreal; Dianna B Roberts; Philip J Stephens; Yi-Jue Zhao; Li Zhang; Mutsumi Mitani; Randal S Weber; Scott M Lippman; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Philip J Stephens; Helen R Davies; Yoshitsugu Mitani; Peter Van Loo; Adam Shlien; Patrick S Tarpey; Elli Papaemmanuil; Angela Cheverton; Graham R Bignell; Adam P Butler; John Gamble; Stephen Gamble; Claire Hardy; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Mark Maddison; Keiran Raine; Serena Nik-Zainal; Sarah O'Meara; Jon W Teague; Ignacio Varela; David C Wedge; Ian Whitmore; Scott M Lippman; Ultan McDermott; Michael R Stratton; Peter J Campbell; Adel K El-Naggar; P Andrew Futreal Journal: J Clin Invest Date: 2013-06-17 Impact factor: 14.808
Authors: Anna Marcinow; Enver Ozer; Theodoros Teknos; Lai Wei; Agnes Hurtuk; Matthew Old; Amit Agrawal; Ricardo Carrau; Obiajulu H Iwenofu Journal: Head Neck Date: 2014-02-01 Impact factor: 3.147
Authors: Allen S Ho; Kasthuri Kannan; David M Roy; Luc G T Morris; Ian Ganly; Nora Katabi; Deepa Ramaswami; Logan A Walsh; Stephanie Eng; Jason T Huse; Jianan Zhang; Igor Dolgalev; Kety Huberman; Adriana Heguy; Agnes Viale; Marija Drobnjak; Margaret A Leversha; Christine E Rice; Bhuvanesh Singh; N Gopalakrishna Iyer; C Rene Leemans; Elisabeth Bloemena; Robert L Ferris; Raja R Seethala; Benjamin E Gross; Yupu Liang; Rileen Sinha; Luke Peng; Benjamin J Raphael; Sevin Turcan; Yongxing Gong; Nikolaus Schultz; Seungwon Kim; Simion Chiosea; Jatin P Shah; Chris Sander; William Lee; Timothy A Chan Journal: Nat Genet Date: 2013-05-19 Impact factor: 38.330
Authors: Patrick M Dillon; Samhita Chakraborty; Christopher A Moskaluk; Prashant J Joshi; Christopher Y Thomas Journal: Head Neck Date: 2015-06-16 Impact factor: 3.147
Authors: Bin Xu; Esther Drill; Allen Ho; Alan Ho; Lara Dunn; Carlos Nicolas Prieto-Granada; Timothy Chan; Ian Ganly; Ronald Ghossein; Nora Katabi Journal: Am J Surg Pathol Date: 2017-10 Impact factor: 6.394
Authors: Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808
Authors: Niels J Rupp; Ulrike Camenisch; Kati Seidl; Elisabeth J Rushing; Nanina Anderegg; Martina A Broglie; David Holzmann; Grégoire B Morand Journal: Head Neck Pathol Date: 2019-09-30